BiotechBreakthroughs

[BiotechBreakthroughs @BioBreakthrough]

$KZIA Prediction: $5 million purchase of GDC-0084 asset from Genentech will ultimately go down as the most brilliant transaction in the history of cancer treatment.

[Marc Lehman @markflowchatter]

William Blair calling "Bullshit" tonite and downgrading $INKT to Market Perform

Old recirculated one patient data

Looks like HC W will get the offering on Monday for keeping quiet earlier in the day

[BiotechBreakthroughs @BioBreakthrough]

$INKT Bleeding lower after hours as sellers try to escape before the probable HCW cap raise hits the wires tonight/early next week. Target $10.

[BiotechBreakthroughs @BioBreakthrough]

$INKT BUYER BEWARE. HCW currently working stock in preparation for a PIPE likely in the $10-15 range. Chasers at current levels going to lose 3/4 of their investment imminently.

[BiotechBreakthroughs @BioBreakthrough]

$INKT OLD NEWS -- From May 15 press release: "A peer-reviewed publication expected in the first half of 2025 will detail a complete remission in a patient with metastatic testicular cancer treated in MiNK’s Phase 1 trial with a single infusion of agenT-797."

[BiotechBreakthroughs @BioBreakthrough]

$INKT CAUTION: Today's news is NOT NEW, previously reported in a press release on May 15. Company will use this unwarranted surge in shares to raise funds at steep discount.

[BiotechBreakthroughs @BioBreakthrough]

$KZIA URGENT BREAKING NEWS:

$CMRX JUST ACQUIRED FOR $935 MILLION. Kazia market cap just over $4 million here.
***KAZIA LEAD DRUG IS USED IN COMBINATION THERAPY WITH CMRX LEAD DRUG*** As close to a no-brainer STRONG BUY RIGHT NOW in biotech as you get.
https://t.co/07NfdSzhCm

[BiotechBreakthroughs @BioBreakthrough]

$DWTX "Dogwood is Dogshit: Fair Value = 75 cents." Promoter Pump is over.. dump in progress. Don't get caught holding the bag.

[BiotechBreakthroughs @BioBreakthrough]

$KZIA $CMRX Dordaviprone works best in combination with Kazia's pax, so expect FDA to greenlight. As soon as traders connect the dots, Kazia shares will be re-rated much, much higher.

[Evie Jackson @evierjackson]

Incredibly proud to share the latest work from #DunLab, published in #CancerResearch! We highlight the combination of ONC201 and paxalisib for the treatment of DMG, the preclinical data informing PNOC022. Follow this tweetorial for a summary: (1/10)
https://t.co/rG6RK1t08r

[Evie Jackson @evierjackson]

Incredibly proud to share the latest work from #DunLab, published in #CancerResearch! We highlight the combination of ONC201 and paxalisib for the treatment of DMG, the preclinical data informing PNOC022. Follow this tweetorial for a summary: (1/10)
https://t.co/rG6RK1t08r

[BiotechBreakthroughs @BioBreakthrough]

$KZIA $CMRX Kazia meets with FDA this month to discuss AA. Given current market capitalization, similar PR will launch shares to $20+ instantly.

[BiotechBreakthroughs @BioBreakthrough]

$KZIA $CMRX Kazia meets with FDA this month to discuss AA. Given current market capitalizaiton, s$similar PR will launch shares to $20+ instantly.

[BiotechBreakthroughs @BioBreakthrough]

$KZIA a Strong Buy on the $CMRX move.
https://t.co/l3jMOnK82v

https://t.co/2E1oD4engy

[BiotechBreakthroughs @BioBreakthrough]

$KZIA Clueless low volume sellers in this biotech/healthcare "RFK panic" may wish to consider that GBM took the life of his uncle.

[Ozmosi @OzmosiHealth]

$KZIA Kazia Therapeutics schedules Type C meeting with FDA to discuss potential next steps for Paxalisib in treating newly diagnosed Glioblastoma Multiforme.

More Info: https://t.co/yPyJFjwnyj $XBI $IBB $XPH $PPH

[BiotechBreakthroughs @BioBreakthrough]

$VCNX up 50%, $MNPR down 40% since this post a week ago.

[BiotechBreakthroughs @BioBreakthrough]

$VCNX Tiny biotech trading under cash foreshadowing PROMISING ALZHEIMER'S DATA in exactly one week.
BUY $VCNX, SELL $MNPR is the prudent trade.

[BiotechBreakthroughs @BioBreakthrough]

$VCNX Tiny biotech trading under cash foreshadowing PROMISING ALZHEIMER'S DATA in exactly one week.
BUY $VCNX, SELL $MNPR is the prudent trade.

[BiotechBreakthroughs @BioBreakthrough]

$VCNX Risk-reward here is EXPONENTIALLY more favorable than buying $MNPR. Monopar simply paying for the right to use a drug (really shouldn't even be trading up on this). Expecting a much more significant partnership announcement for Vaccinex. $VCNX current mkt cap 1/10 of $MNPR.

[BiotechBreakthroughs @BioBreakthrough]

$VCNX Shares trade under cash, majority of float owned by insiders. CEO has purchased millions of shares. $MNPR

[BiotechBreakthroughs @BioBreakthrough]

$VCNX MAJOR PARTNERSHIP ANNOUNCEMENT implied in recent PR ... the same news that ignited $MNPR

[BiotechBreakthroughs @BioBreakthrough]

$VCNX VACCINEX TO REPORT PROMISING NEW EFFICACY DATA AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE one week from today. $VCNX the next $MNPR?